China: Food and Drugs Law

China's pharmaceutical and life sciences regulatory landscape underwent significant transformation in 2026, with major policy updates spanning drug approval processes, medical device quality standards, and healthcare facility management. The National Medical Products Administration introduced priority review pathways for chemical APIs and updated cosmetics registration requirements, while new medical device production standards took effect nationwide.

中国国家知識産権局の復審・無効審理部が上海市で医薬品特許紛争の早期解決制度における行政裁決について調査を実施し、関連企業や関係者

The Asia-Pacific Economic Cooperation held a High-Level Policy Dialogue on Agricultural Biotechnology in Dalian, China, where participants explored how genome technologies are transforming food production across the region. Experts demonstrated innovations ranging from fish bred with fewer bones to rice varieties designed for diabetic populations, while addressing the critical challenge of public perception and regulatory frameworks. The dialogue emphasized science-based regulation and consumer education as

近日，国家知识产权局遴选出十件关注度高、影响力大、具备指导价值的2025年度专利复审无效典型案例，以深入阐释专利审查标准，明晰专利保护规则...

国家知识产权局公布2025年度十件专利复审无效典型案例，涵盖生物医药、人工智能、视频编码等多个技术领域。这些案例深入阐释了专利审查标准A

In 2026, Chinese regulators have continued their focus on anti-corruption enforcement in the life sciences industry.

This China Newsletter provides an overview of key developments in the following areas...

On April 21, 2025, the Supreme People's Court (SPC) released the Annual Report on the Issues of Law Application in intellectual property (IP) cases...

调研表明全球高收入人群及中国消费者正在削减支出